Hispanic Americans

Female hispanic patients with major depressive disorder reported fewer side effects when treated with fluoxetine (or paroxetine) compared to non-Hispanic female patients.
Hispanic patients had 2.2 +/- 2.0 side effect complaints versus 5.1 +/- 2.5 for non-Hispanic patients (p<0.005). No differences were reported in response (HAM-D scores), side effects, or attrition rates between fluoxetine- and paroxetine-treated subjects.
N = 26: 13 Hispanic and 13 non-Hispanic patients in San Diego, Cal., prospective open-label study of paroxetine (N=18) and fluoxetine (N=8); Alonso et al., 1997.

Hispanic patients with major depressive disorder seem to have similar response rates compared to other nefazodone trials with non-Hispanic patients. Fifty-eight percent of the full in-tent-to-treat sample were rated as responders at the end of the 8-week trial. A higher drop-out rate was found compared to previous trials with predominantly non-Hispanic White subjects using nefazodone (42 % versus 21-33%). The authors did not find evidence that supports the need for lower doses of nefazodone among Hispanics (no elevated side effect reports, no lower mean endpoint doses, nor any reduction in the overall efficacy).
(N = 50, open trial with Spanish-speaking outpatients composed of Latin American migrants to the U.S., New York City), Sanchez-Lacay et al., 2001.

Female hispanic patients with major depressive disorder reported fewer side effects when treated with paroxetine (or fluoxetine) compared to non-Hispanic female patients.
Hispanic patients had 2.2 +/- 2.0 side effect complaints versus 5.1 +/- 2.5 for non-Hispanic patients (p<0.005). No differences were reported in response (HAM-D scores), side effects, or attrition rates between fluoxetine- and paroxetine-treated subjects.
N = 26: 13 Hispanic and 13 non-Hispanic patients in San Diego, Cal., prospective open-label study of paroxetine (N=18) and fluoxetine (N=8); Alonso et al., 1997.